Method of treating inflammation
AssigneeCytoSorbents Corporation
InventorsPhillip P. Chan, Wei-Tai Young, Vincent J. Capponi, Thomas D. Golobish, Humayra Begum Ali
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.
Claims18
A method of treating inflammation in a patient comprising administering a therapeutically effective dose of a sorbent for an inflammatory mediator to said patient;
- wherein the sorbent is a biocompatible polymer;
- the biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof,
- the biocompatible polymer having a pore structure such that the total pore volume of pore size in the range of 50 {acute over (Å)} to 3000 {acute over (Å)} is greater than 0.5 cc/g to 3.0 cc/g dry polymer;
- the sorbent being administered orally, via a feeding tube, peritoneally, or rectally;
- wherein said inflammatory mediator is a cytokine resulting from inflammatory bowel disease in said patient, burns to said patient, sepsis in said patient, or exposure of said patient to neurotoxins.
A pharmaceutical kit comprising a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient;
- wherein the sorbent is a biocompatible polymer;
- the biocompatible polymer comprising residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof,
- the biocompatible polymer having a pore structure such that the total pore volume of pore size in the range of 50 {acute over (Å)} to 3000 {acute over (Å)} is greater than 0.5 cc/g to 3.0 cc/g dry polymer;
- the sorbent being administered orally, via a feeding tube, peritoneally, or rectally;
- wherein said inflammatory mediator is a cytokine resulting from inflammatory bowel disease in said patient, burns to said patient, sepsis in said patient, or exposure of said patient to neurotoxins.
Dependencies are inferred from the claim text.